Ipsen's Blockbuster Blitz: Positive Readouts, Double-Barrel M&A, and a Guidance Upgrade
Record 38.6% margin, three positive Phase IIIs, and two late-stage acquisitions redefine Ipsen's growth trajectory.
IPN.PA · Earnings Call · 2026-07-30
A Stellar H1
Ipsen delivered an exceptional first half. Total sales rose 23.5% at constant exchange rates to €2.2 billion, with growth across all three therapeutic areas. CFO Aymeric Le Chatelier highlighted the top-line momentum: “Total sales reached EUR 2.2 billion, growing 23.5% at constant exchange rates.” — Aymeric Le Chatelier, CFO · 2026-07-30 He also underlined the record profitability: “core operating margin improved by 2.5 points to a record level of 38.6% of total sales.” — Aymeric Le Chatelier, CFO · 2026-07-30 That margin outperformance allowed management to lift full-year guidance to sales growth above 20% and a core operating margin above 37%. The strength was broad-based: Rare Disease more than doubled, driven by IQIRVO in PBC and Bylvay, while Neuroscience grew 16.6% on the back of Dysport. Notably, the company's episodic migraine program is a fresh high-momentum theme—Dysport is the first botulinum toxin to show positive Phase III results in this patient population. The company also reiterated its confidence in IQIRVO's peak sales potential, now estimated at €1 billion in PBC alone.A Pipeline on Fire
The real story is the pipeline. Ipsen reported three positive Phase III readouts in the first half: Dysport in chronic and episodic migraine (C-BEOND and E-BEOND) and IQIRVO in PBC (ELSPIRE). CEO David Loew called these "blockbuster potential" and the company is now preparing regulatory submissions. “We have now delivered three positive Phase III readouts, two for Dysport in therapeutics across episodic and chronic migraine, both showing very strong results and one for IQIRVO in PBC through the ASPIRE studies.” — David Loew, CEO · 2026-07-30 The migraine data are particularly meaningful: the episodic result is the first of its kind for a toxin. Dysport in migraine could meaningfully expand the patient population, and the company is planning a launch in the second half of 2027. Mari Scheiffele, the commercial officer, noted that the global botulinum toxin market for therapeutics stands at approximately €4 billion, with chronic migraine accounting for around 40% of that value.Two Bolt-Ons to Accelerate Growth
Beyond internal progress, Ipsen announced two late-stage acquisitions: Kartos Therapeutics and its MDM2 inhibitor Navtemadlin for myelofibrosis, and Memo Therapeutics with Potravitug for BK polyomavirus nephropathy. These fit squarely into the company's stated strategy of external innovation. The CFO noted the company retains "more than EUR 2 billion of pro forma firepower" after these deals. This is a significant strategic pivot toward hematology and transplant. The myelofibrosis opportunity appears twice in the keyword gainers list, indicating a strong theme. The company expects to close the Kartos transaction in Q3 and launch Navtemadlin as early as 2028, subject to positive Phase III data.Counterpoints and Outlook
Not everything went perfectly: the BOLD trial in biliary atresia for Bylvay missed its primary endpoint, though the company remains confident in Bylvay's growth in PFIC and Alagille. The guidance upgrade was aided by delayed generic competition for Somatuline, but management expects some impact in 2027. The company's confidence is not new: as CFO Aymeric Le Chatelier said in February, “we are clearly highly confident to 2027. I will provide a guidance for 2027 when it's going to be time.” — David Loew, CEO · 2026-02-12 And David Loew in October reiterated the appetite for late-stage assets: “we are absolutely looking at late-stage deals, and we have ample firepower.” — David Loew, CEO · 2025-10-22 The strategic pivot is a long-term play, and the recent deals and readouts are evidence of that commitment.To conclude, H1 2026 shows Ipsen delivering strongly on its strategy to accelerate growth of key medicines and expanding the pipeline. We delivered very strong first half sales growth, upgraded our full year guidance and maintained strong cash generation, giving us the flexibility to keep investing behind the future growth.